filgotinib vs Zemprocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK1 · full Rheumatoid Arthritis pipeline
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)
Result source: NCT02889796
Zemprocitinib
Developed by Lynk Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | filgotinib | Zemprocitinib |
|---|---|---|
| ACR20 | 76.6% vs 49.9%+26.7 vs placeboNCT0288979651 other results
| —Not posted · NCT06276998 |
| ACR50 | 64.2% vs 66%−1.8 vs placeboNCT0288979687 other results
| —Not posted · NCT06276998 |
| ACR70 | 44.4% vs 37.7%+6.7 vs placeboNCT0288979687 other results
| —Not posted · NCT06276998 |
| DAS28-CRP remission | 54.5% vs 50.8%+3.7 vs placeboNCT0288979635 other results
| —Not posted · NCT06276998 |
| HAQ-DI, change | -0.9 vs -0.7−0.2 vs placeboNCT0288979636 other results
| —Not posted · NCT06276998 |
| Modified Sharp score, change | 0.2 vs 0.9−0.7 vs placeboNCT028897969 other results
| —Not posted · NCT06276998 |
ACR20
- filgotinib
- 76.6% vs 49.9%+26.7 vs placeboNCT02889796
51 other results
- 69.8% vs 49.9% NCT02889796
- 66% vs 31.1% NCT02873936
- 57.5% vs 31.1% NCT02873936
- 78.1% vs 71.4% NCT02886728
- 81% vs 71.4% NCT02886728
- 80.2% vs 71.4% NCT02886728
- 82.9% vs 85.9% NCT02889796
- 82.9% vs 86.9% NCT02889796
- 78.1% vs 59.2% NCT02889796
- 51.6% vs 31.8% NCT02889796
- 37.3% vs 14.9% NCT02889796
- 79.6% vs 85.9% NCT02889796
- 79.2% vs 86.9% NCT02889796
- 77.7% vs 59.2% NCT02889796
- 45.6% vs 31.8% NCT02889796
- 27.5% vs 14.9% NCT02889796
- 69.4% vs 34.5% NCT02873936
- 51.7% vs 25.7% NCT02873936
- 54.9% vs 34.5% NCT02873936
- 44.4% vs 25.7% NCT02873936
- 74.8% vs 61.8% NCT02886728
- 76.2% vs 68.3% NCT02886728
- 71.4% vs 59.4% NCT02886728
- 52.4% vs 33.4% NCT02886728
- 39.5% vs 16.6% NCT02886728
- 75% vs 61.8% NCT02886728
- 75.5% vs 68.3% NCT02886728
- 76.7% vs 59.4% NCT02886728
- 62.3% vs 33.4% NCT02886728
- 42.1% vs 16.6% NCT02886728
- 73.4% vs 61.8% NCT02886728
- 73.4% vs 68.3% NCT02886728
- 72% vs 59.4% NCT02886728
- 55.6% vs 33.4% NCT02886728
- 37.2% vs 16.6% NCT02886728
- 72.5% vs 29.2% NCT01894516
- 68.6% vs 44.2% NCT01888874
- 65.7% vs 29.2% NCT01894516
- 63.5% vs 44.2% NCT01888874
- 78.6% vs 44.2% NCT01888874
- 66.7% vs 29.2% NCT01894516
- 56.1% vs 44.2% NCT01888874
- 60% vs 44.2% NCT01888874
- 57% vs 44.2% NCT01888874
- 73.3% vs 41.9% NCT01888874
- 61.2% vs 41.9% NCT01888874
- 79.8% vs 41.9% NCT01888874
- 54.9% vs 41.9% NCT01888874
- 60% vs 41.9% NCT01888874
- 55.8% vs 41.9% NCT01888874
- 81% vs 40.9% NCT02885181
- Zemprocitinib
- —Not posted · NCT06276998
ACR50
- filgotinib
- 64.2% vs 66%−1.8 vs placeboNCT02889796
87 other results
- 63.2% vs 63.4% NCT02889796
- 57.9% vs 33.3% NCT02889796
- 47.2% vs 19.8% NCT02889796
- 22.3% vs 5.9% NCT02889796
- 9.1% vs 1.1% NCT02889796
- 60.6% vs 66% NCT02889796
- 57.7% vs 63.4% NCT02889796
- 52.7% vs 33.3% NCT02889796
- 36.5% vs 19.8% NCT02889796
- 12.9% vs 5.9% NCT02889796
- 5.8% vs 1.1% NCT02889796
- 45.6% vs 18.9% NCT02873936
- 42.9% vs 14.9% NCT02873936
- 22.4% vs 7.4% NCT02873936
- 35.3% vs 18.9% NCT02873936
- 32% vs 14.9% NCT02873936
- 21.6% vs 7.4% NCT02873936
- 61.4% vs 48.3% NCT02886728
- 58.6% vs 48.6% NCT02886728
- 58.1% vs 45.7% NCT02886728
- 45.7% vs 28.4% NCT02886728
- 25.7% vs 9.4% NCT02886728
- 16.2% vs 2.9% NCT02886728
- 62.3% vs 48.3% NCT02886728
- 60.6% vs 48.6% NCT02886728
- 61.5% vs 45.7% NCT02886728
- 53.1% vs 28.4% NCT02886728
- 29.3% vs 9.4% NCT02886728
- 13% vs 2.9% NCT02886728
- 59.4% vs 48.3% NCT02886728
- 55.6% vs 48.6% NCT02886728
- 57% vs 45.7% NCT02886728
- 44.4% vs 28.4% NCT02886728
- 20.8% vs 9.4% NCT02886728
- 9.2% vs 2.9% NCT02886728
- 50% vs 16.3% NCT01888874
- 43.5% vs 11.1% NCT01894516
- 43% vs 15.1% NCT01888874
- 31.9% vs 5.6% NCT01894516
- 33.7% vs 12.8% NCT01888874
- 23.2% vs 4.2% NCT01894516
- 17.4% vs 7% NCT01888874
- 21.7% vs 4.2% NCT01894516
- 10.5% vs 5.8% NCT01888874
- 7.2% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 47.1% vs 16.3% NCT01888874
- 54.8% vs 16.3% NCT01888874
- 37.1% vs 11.1% NCT01894516
- 37.6% vs 15.1% NCT01888874
- 54.8% vs 15.1% NCT01888874
- 25.7% vs 5.6% NCT01894516
- 35.3% vs 12.8% NCT01888874
- 45.2% vs 12.8% NCT01888874
- 18.6% vs 4.2% NCT01894516
- 32.9% vs 7% NCT01888874
- 34.5% vs 7% NCT01888874
- 7.1% vs 4.2% NCT01894516
- 20% vs 5.8% NCT01888874
- 21.4% vs 5.8% NCT01888874
- 10% vs 1.4% NCT01894516
- 4.7% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 35.4% vs 16.3% NCT01888874
- 35.3% vs 16.3% NCT01888874
- 34.7% vs 11.1% NCT01894516
- 32.9% vs 15.1% NCT01888874
- 34.1% vs 15.1% NCT01888874
- 16.7% vs 5.6% NCT01894516
- 26.8% vs 12.8% NCT01888874
- 34.1% vs 12.8% NCT01888874
- 15.3% vs 4.2% NCT01894516
- 13.4% vs 7% NCT01888874
- 18.8% vs 7% NCT01888874
- 5.6% vs 4.2% NCT01894516
- 7.3% vs 5.8% NCT01888874
- 11.8% vs 5.8% NCT01888874
- 1.4% vs 1.4% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 7.1% vs 1.2% NCT01888874
- 34.9% vs 16.3% NCT01888874
- 27.9% vs 15.1% NCT01888874
- 25.6% vs 12.8% NCT01888874
- 15.1% vs 7% NCT01888874
- 7% vs 5.8% NCT01888874
- 3.5% vs 1.2% NCT01888874
- 47.6% vs 22.7% NCT02885181
- Zemprocitinib
- —Not posted · NCT06276998
ACR70
- filgotinib
- 44.4% vs 37.7%+6.7 vs placeboNCT02889796
87 other results
- 40.2% vs 34.6% NCT02889796
- 36.2% vs 14.9% NCT02889796
- 26.1% vs 6.7% NCT02889796
- 9.1% vs 1.5% NCT02889796
- 2.7% vs 0.4% NCT02889796
- 39% vs 37.7% NCT02889796
- 35.4% vs 34.6% NCT02889796
- 29.6% vs 14.9% NCT02889796
- 18.5% vs 6.7% NCT02889796
- 3.3% vs 1.5% NCT02889796
- 1.3% vs 0.4% NCT02889796
- 32% vs 8.1% NCT02873936
- 21.8% vs 6.8% NCT02873936
- 6.1% vs 2.7% NCT02873936
- 20.3% vs 8.1% NCT02873936
- 14.4% vs 6.8% NCT02873936
- 8.5% vs 2.7% NCT02873936
- 45.2% vs 29.8% NCT02886728
- 39.5% vs 32.2% NCT02886728
- 40% vs 26% NCT02886728
- 29% vs 13.2% NCT02886728
- 11.4% vs 3.8% NCT02886728
- 4.3% vs 0.7% NCT02886728
- 47.8% vs 29.8% NCT02886728
- 45.9% vs 32.2% NCT02886728
- 43.8% vs 26% NCT02886728
- 32.9% vs 13.2% NCT02886728
- 13% vs 3.8% NCT02886728
- 3.1% vs 0.7% NCT02886728
- 40.1% vs 29.8% NCT02886728
- 37.2% vs 32.2% NCT02886728
- 40.1% vs 26% NCT02886728
- 27.1% vs 13.2% NCT02886728
- 6.3% vs 3.8% NCT02886728
- 1.9% vs 0.7% NCT02886728
- 29.1% vs 9.3% NCT01888874
- 13% vs 2.8% NCT01894516
- 24.4% vs 8.1% NCT01888874
- 17.4% vs 2.8% NCT01894516
- 18.6% vs 7% NCT01888874
- 11.6% vs 1.4% NCT01894516
- 4.7% vs 3.5% NCT01888874
- 4.3% vs 2.8% NCT01894516
- 5.8% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 1.2% vs 1.2% NCT01888874
- 32.9% vs 9.3% NCT01888874
- 39.3% vs 9.3% NCT01888874
- 18.6% vs 2.8% NCT01894516
- 21.2% vs 8.1% NCT01888874
- 31% vs 8.1% NCT01888874
- 11.4% vs 2.8% NCT01894516
- 23.5% vs 7% NCT01888874
- 27.4% vs 7% NCT01888874
- 5.7% vs 1.4% NCT01894516
- 14.1% vs 3.5% NCT01888874
- 10.7% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 7.1% vs 1.2% NCT01888874
- 3.6% vs 1.2% NCT01888874
- 1.4% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 4.8% vs 1.2% NCT01888874
- 22% vs 9.3% NCT01888874
- 23.5% vs 9.3% NCT01888874
- 8.3% vs 2.8% NCT01894516
- 15.9% vs 8.1% NCT01888874
- 18.8% vs 8.1% NCT01888874
- 6.9% vs 2.8% NCT01894516
- 11% vs 7% NCT01888874
- 14.1% vs 7% NCT01888874
- 8.3% vs 1.4% NCT01894516
- 7.3% vs 3.5% NCT01888874
- 9.4% vs 3.5% NCT01888874
- 1.4% vs 2.8% NCT01894516
- 2.4% vs 1.2% NCT01888874
- 5.9% vs 1.2% NCT01888874
- 0% vs 0% NCT01894516
- 0% vs 1.2% NCT01888874
- 2.4% vs 1.2% NCT01888874
- 20.9% vs 9.3% NCT01888874
- 14% vs 8.1% NCT01888874
- 9.3% vs 7% NCT01888874
- 5.8% vs 3.5% NCT01888874
- 2.3% vs 1.2% NCT01888874
- 1.2% vs 1.2% NCT01888874
- 38.1% vs 13.6% NCT02885181
- Zemprocitinib
- —Not posted · NCT06276998
DAS28-CRP remission
- filgotinib
- 54.5% vs 50.8%+3.7 vs placeboNCT02889796
35 other results
- 50.3% vs 46.1% NCT02889796
- 48.4% vs 16.2% NCT02889796
- 34.1% vs 9.3% NCT02889796
- 13.7% vs 2.9% NCT02889796
- 5.1% vs 0.6% NCT02889796
- 44.8% vs 50.8% NCT02889796
- 42.9% vs 46.1% NCT02889796
- 35.2% vs 16.2% NCT02889796
- 23.8% vs 9.3% NCT02889796
- 8.8% vs 2.9% NCT02889796
- 1.7% vs 0.6% NCT02889796
- 30.6% vs 12.2% NCT02873936
- 22.4% vs 8.1% NCT02873936
- 10.2% vs 2.7% NCT02873936
- 26.1% vs 12.2% NCT02873936
- 25.5% vs 8.1% NCT02873936
- 11.8% vs 2.7% NCT02873936
- 46.2% vs 31.5% NCT02886728
- 43.3% vs 34.4% NCT02886728
- 42.4% vs 29.1% NCT02886728
- 29.5% vs 17.1% NCT02886728
- 19.5% vs 4.8% NCT02886728
- 10% vs 1% NCT02886728
- 53.4% vs 31.5% NCT02886728
- 52.6% vs 34.4% NCT02886728
- 54.1% vs 29.1% NCT02886728
- 39.7% vs 17.1% NCT02886728
- 16.6% vs 4.8% NCT02886728
- 7.2% vs 1% NCT02886728
- 43% vs 31.5% NCT02886728
- 42% vs 34.4% NCT02886728
- 42.5% vs 29.1% NCT02886728
- 31.9% vs 17.1% NCT02886728
- 15% vs 4.8% NCT02886728
- 4.3% vs 1% NCT02886728
- Zemprocitinib
- —Not posted · NCT06276998
HAQ-DI, change
- filgotinib
- -0.9 vs -0.7−0.2 vs placeboNCT02889796
36 other results
- -0.9 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.7 vs -0.4 NCT02889796
- -0.4 vs -0.3 NCT02889796
- -0.3 vs -0.1 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.7 NCT02889796
- -0.8 vs -0.6 NCT02889796
- -0.6 vs -0.4 NCT02889796
- -0.3 vs -0.3 NCT02889796
- -0.2 vs -0.1 NCT02889796
- -0.8 vs -0.4 NCT02873936
- -0.6 vs -0.2 NCT02873936
- -0.4 vs -0.2 NCT02873936
- -0.6 vs -0.4 NCT02873936
- -0.5 vs -0.2 NCT02873936
- -0.3 vs -0.2 NCT02873936
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.3 vs -0.2 NCT02886728
- -1 vs -0.9 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.6 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -1.0 vs -0.9 NCT02886728
- -0.9 vs -0.9 NCT02886728
- -0.9 vs -0.8 NCT02886728
- -0.8 vs -0.6 NCT02886728
- -0.5 vs -0.3 NCT02886728
- -0.4 vs -0.2 NCT02886728
- -0.7 vs -0.4 NCT02885181
- Zemprocitinib
- —Not posted · NCT06276998
Modified Sharp score, change
- filgotinib
- 0.2 vs 0.9−0.7 vs placeboNCT02889796
9 other results
- 0.1 vs 0.4 NCT02889796
- 0.5 vs 0.9 NCT02889796
- 0.2 vs 0.4 NCT02889796
- 0.3 vs 0.8 NCT02886728
- -0.0 vs 0.5 NCT02886728
- 0.3 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- 0.2 vs 0.8 NCT02886728
- 0.2 vs 0.5 NCT02886728
- Zemprocitinib
- —Not posted · NCT06276998
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zemprocitinib: no structured comparison results are available for Rheumatoid Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. filgotinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | filgotinib |
|---|---|
| Dropout rate | 8.8%200 mga NCT02873936 · Phase 3 show 26 more results15%100 mg NCT02873936 · Phase 3 17.1%200 mg NCT02886728 · Phase 3 · monotherapy 17.3%200 mg NCT02886728 · Phase 3 · combination 15.5%100 mg NCT02886728 · Phase 3 · combination 11.1%200 mg NCT02889796 · Phase 3 12.1%100 mg NCT02889796 · Phase 3 52.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 53.7%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 61.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 0%Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 67.6%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 66.5%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 4.3%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 6.9%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 7%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 8.2%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 5.9%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 7.3%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 10.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2%200 mga NCT02873936 · Phase 3 show 26 more results3.3%100 mg NCT02873936 · Phase 3 2.4%200 mg NCT02886728 · Phase 3 · monotherapy 3.1%200 mg NCT02886728 · Phase 3 · combination 2.4%100 mg NCT02886728 · Phase 3 · combination 3.6%200 mg NCT02889796 · Phase 3 1.7%100 mg NCT02889796 · Phase 3 12.3%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 13.4%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 14%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 12.2%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 33.2%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 42.6%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 1.4%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 1.2%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 1.2%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 2.4%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.5%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.1%200 mga NCT02873936 · Phase 3 show 26 more results5.2%100 mg NCT02873936 · Phase 3 8.1%200 mg NCT02886728 · Phase 3 · monotherapy 6.3%200 mg NCT02886728 · Phase 3 · combination 6.3%100 mg NCT02886728 · Phase 3 · combination 7.4%200 mg NCT02889796 · Phase 3 8.3%100 mg NCT02889796 · Phase 3 24.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 22.1%200 mg NCT03025308 · Phase 3 · registry result, not featured evidence 24.6%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 25.9%100 mg NCT03025308 · Phase 3 · registry result, not featured evidence 3.7%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 12.8%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence 14.3%200 mg NCT03926195 · Phase 2 · registry result, not featured evidence —Filgonitib NCT03926195 · Phase 2 · registry result, not featured evidence 16.9%Filgotinib Darwin 1 NCT02065700 · Phase 2 · registry result, not featured evidence 19.8%Filgotinib Darwin 2 NCT02065700 · Phase 2 · registry result, not featured evidence 0% NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 4.3%200 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 3.5%100 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.8%50 mg QD NCT01894516 · Phase 2 · registry result, not featured evidence 2.3%200 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 3.6%100 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 3.4%100 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT01888874 · Phase 2 · registry result, not featured evidence 2.3%25 mg BID NCT01888874 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 mga nasopharyngitis 10.2% (placebo 4.7%) bronchitis 5.4% (placebo 5.4%) headache 5.4% (placebo 1.4%) NCT02873936 · Phase 3 show 25 more results100 mg headache 5.9% (placebo 1.4%) nasopharyngitis 5.9% (placebo 4.7%) upper respiratory tract infection 5.9% (placebo 4.1%) NCT02873936 · Phase 3 200 mg nausea 12.3% upper respiratory tract infection 10.1% alanine aminotransferase increased 5.5% NCT02886728 · Phase 3 · combination 200 mg nasopharyngitis 9.1% (placebo 5.3%) upper respiratory tract infection 8.6% (placebo 2.9%) nausea 5.5% (placebo 1.5%) NCT02889796 · Phase 3 100 mg upper respiratory tract infection 10.2% (placebo 2.9%) nasopharyngitis 10% (placebo 5.3%) alanine aminotransferase increased 5.2% (placebo 2.3%) NCT02889796 · Phase 3 200 mg covid-19 18.3% nasopharyngitis 13.1% upper respiratory tract infection 11% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg covid-19 17.3% upper respiratory tract infection 13.1% rheumatoid arthritis 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 15.3% nasopharyngitis 15.1% rheumatoid arthritis 13.9% NCT03025308 · Phase 3 · registry result, not featured evidence 100 mg covid-19 18.5% rheumatoid arthritis 12.2% upper respiratory tract infection 11.9% NCT03025308 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 7.4% (placebo 7.3%) dyslipidaemia 3.7% (placebo 0%) headache 3.7% (placebo 1.8%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg covid-19 15.4% (placebo 0%) ankylosing spondylitis 7.7% (placebo 0%) latent tuberculosis 7.7% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 57.1% (placebo 7.3%) covid-19 42.9% (placebo 0%) alanine aminotransferase increased 14.3% (placebo 0%) NCT03926195 · Phase 2 · registry result, not featured evidence hypertension 15.1% urinary tract infection 14.5% nasopharyngitis 14.1% NCT02065700 · Phase 2 · registry result, not featured evidence mycobacterium tuberculosis complex test positive 16.5% upper respiratory tract infection 15.3% hypercholesterolaemia 12.4% NCT02065700 · Phase 2 · registry result, not featured evidence asthenia 9.5% (placebo 0%) blood creatine phosphokinase increased 4.8% (placebo 0%) dyspepsia 4.8% (placebo 0%) NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy 200 mg QD anaemia 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 2.8%) urinary tract infection 5.8% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 100 mg QD urinary tract infection 8.2% (placebo 1.4%) hypercholesterolaemia 5.9% (placebo 4.2%) hypertriglyceridaemia 5.9% (placebo 1.4%) NCT01894516 · Phase 2 · registry result, not featured evidence 50 mg QD headache 5.6% (placebo 1.4%) hypercholesterolaemia 5.6% (placebo 4.2%) hypertension 4.2% (placebo 5.6%) NCT01894516 · Phase 2 · registry result, not featured evidence 200 mg QD headache 7% (placebo 4.7%) hypercholesterolaemia 5.8% (placebo 0%) hypertension 4.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg BID hypercholesterolaemia 4.8% (placebo 0%) nasopharyngitis 4.8% (placebo 4.7%) headache 2.4% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence 100 mg QD hypertension 5% (placebo 2.3%) nasopharyngitis 2.5% (placebo 4.7%) upper respiratory tract infection 1.7% (placebo 1.2%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg BID upper respiratory tract infection 5.1% (placebo 1.2%) vomiting 5.1% (placebo 1.2%) hypertension 3.4% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 9.8% (placebo 4.7%) nausea 8.5% (placebo 3.5%) hypertension 3.7% (placebo 2.3%) NCT01888874 · Phase 2 · registry result, not featured evidence 25 mg BID headache 7% (placebo 4.7%) gastroenteritis 5.8% (placebo 0%) nasopharyngitis 4.7% (placebo 4.7%) NCT01888874 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
filgotinib
show 51 more results
show 36 more results
show 29 more results
show 30 more results
show 35 more results
show 54 more results
show 87 more results
show 87 more results
show 35 more results
show 35 more results
show 35 more results
show 35 more results
+ 266 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · Zemprocitinib's landscape